Literature DB >> 12812312

Morphology of necrosis and repair after transcoronary ethanol ablation of septal hypertrophy.

Ute Raute-Kreinsen1.   

Abstract

The transcoronary ethanol ablation of septum hypertrophy (TASH) results in a necrosis of the myocardium. In contrast to the ischemically induced necrosis, there is not any phagocytosis caused by leukocytes and macrophages, nor does transformation into granulation tissue occur. Even six months after the application of ethanol, the myofibrils can be identified as "ghost cells" surrounded by a web of collagen fibers. This special forming of a scar, unknown to this day, is documented by 13 patients who died between 25 minutes and two years after ethanol-induced ablation of the hypertrophic septum in hypertrophic obstructive cardiomyopathiy (HOCM).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12812312     DOI: 10.1078/0344-0338-00364

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  11 in total

1.  Low occurrence of ventricular arrhythmias after alcohol septal ablation in high-risk patients with hypertrophic obstructive cardiomyopathy.

Authors:  Angelos G Rigopoulos; Silke Daci; Barbara Pfeiffer; Konstadia Papadopoulou; Anna Neugebauer; Hubert Seggewiss
Journal:  Clin Res Cardiol       Date:  2016-06-06       Impact factor: 5.460

Review 2.  Review on sudden death risk reduction after septal reduction therapies in hypertrophic obstructive cardiomyopathy.

Authors:  Angelos G Rigopoulos; Muhammad Ali; Elena Abate; Marios Matiakis; Hannes Melnyk; Sophie Mavrogeni; Dionyssios Leftheriotis; Boris Bigalke; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2019-05       Impact factor: 4.214

3.  Pathological effects of alcohol septal ablation for hypertrophic obstructive cardiomyopathy.

Authors:  A L Baggish; R N Smith; I Palacios; G J Vlahakes; D M Yoerger; M H Picard; P A Lowry; I-K Jang; M A Fifer
Journal:  Heart       Date:  2006-06-28       Impact factor: 5.994

4.  Septal myectomy after failed septal alcohol ablation.

Authors:  Eduard Quintana; Pietro Bajona; María José Arguis; Susanna Prat-González
Journal:  Ann Cardiothorac Surg       Date:  2017-07

5.  The risk of non-sustained ventricular tachycardia after percutaneous alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy.

Authors:  Mariusz Klopotowski; Lidia Chojnowska; Lukasz A Malek; Renata Maczynska; Krzysztof Kukula; Marcin Demkow; Adam Witkowski; Maciej Dabrowski; Maciej Karcz; Rafal Baranowski; Beata Kusmierczyk-Droszcz; Mariusz Kruk; Jacek Jamiolkowski; Mariusz Kusmierczyk; Lukasz Szumowski; Witold Ruzyllo
Journal:  Clin Res Cardiol       Date:  2010-02-11       Impact factor: 5.460

6.  Maturation of Lesions Induced by Myocardial Cavitation-Enabled Therapy.

Authors:  Xiaofang Lu; Douglas L Miller; Chunyan Dou; Yiying I Zhu; Mario L Fabiilli; Gabe E Owens; Oliver D Kripfgans
Journal:  Ultrasound Med Biol       Date:  2016-04-14       Impact factor: 2.998

Review 7.  Sudden death in hypertrophic cardiomyopathy.

Authors:  Barry J Maron
Journal:  J Cardiovasc Transl Res       Date:  2009-11-13       Impact factor: 4.132

8.  Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy.

Authors:  H Seggewiss; A Rigopoulos; D Welge; P Ziemssen; L Faber
Journal:  Clin Res Cardiol       Date:  2007-09-27       Impact factor: 5.460

9.  Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience.

Authors:  Horst Kuhn; Thorsten Lawrenz; Frank Lieder; Christian Leuner; Claudia Strunk-Mueller; Ludger Obergassel; Markus Bartelsmeier; Christoph Stellbrink
Journal:  Clin Res Cardiol       Date:  2007-12-10       Impact factor: 5.460

Review 10.  The "1st septal unit" in hypertrophic obstructive cardiomyopathy: a newly recognized anatomo-functional entity, identified during recent alcohol septal ablation experience.

Authors:  Paolo Angelini
Journal:  Tex Heart Inst J       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.